VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)
Shots:
- The P-III study involves assessing of PH94B vs PBO in 22 patients with Social Anxiety Disorder
- P-III study results: @1wk. decrease in average peak Subjective Units of Distress scores; decrease in Liebowitz Social Anxiety Scale (LSAS) avoidance scores; no Adverse Events; safety profile was excellent; Presented at Anxiety and Depression Association of America Annual Conference 2019
- PH94B is a neuroactive nasal spray contains pherines involves activation of chemosensory receptors that triggers neural circuits in the brain suppressing fear and anxiety and will be evaluated in P-III development program as an on-demand PRN treatment for SAD
Click here to read full press release/ article | Ref: VistaGen Therapeutics | Image: Twitter